Advertisement

Topics

Eiger Bio’s Hypertension Drug Flunks Phase 2 Trial, Shares Tumble

16:44 EST 16 Jan 2018 | Xconomy

An Eiger BioPharmaceuticals drug being tested for the treatment of pulmonary arterial hypertension has failed a mid-stage study, and the drug developer says it will stop work on the compound for that condition. News of the clinical trial failure cut the value of shares in Palo Alto, CA, based Eiger (NASDAQ: EIGR) nearly in half. […]

Original Article: Eiger Bio’s Hypertension Drug Flunks Phase 2 Trial, Shares Tumble

NEXT ARTICLE

More From BioPortfolio on "Eiger Bio’s Hypertension Drug Flunks Phase 2 Trial, Shares Tumble"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology Products
BioPortfolio lists over 550 biotechnology products - please open http://www.bioportfolio.com/channels?category_id=5 Direct topic pages: Actos Advair Biopharmaceuticals Biosimilars Biotherapeutics GMO Crops Lipitor ...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Pulmonary Hypertension
Pulmonary arterial hypertension (PAH) is a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs of affected individuals. Symptoms can range from mild breathles...